Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience
- G. Brandon Gunn, MD
- Adam S. Garden, MD
- Rong Ye, MSc
- Noveen Ausat, BA
- Kristina R. Dahlstrom, PhD
- William H. Morrison, MD
- C. David Fuller, MD, PhD
- Jack Phan, MD, PhD
- Jay P. Reddy, MD, PhD
- Shalin J. Shah, MD
- Lauren L. Mayo, MD
- Stephen G. Chun, MD
- Gregory M. Chronowski, MD
- Amy C. Moreno, MD
- Jeffery N. Myers, MD, PhD
- Ehab Y. Hanna, MD
- Bita Esmaeli, MD
- Maura L. Gillison, MD, PhD
- Renata Ferrarotto, MD
- Katherine A. Hutcheson, PhD
- Mark S. Chambers, DMD, MS
- Lawrence E. Ginsberg, MD
- Adel K. El-Naggar, MD, PhD
- David I. Rosenthal, MD
- Xiaorong Ronald Zhu, PhD
- Steven J. Frank, MD
DOIAbstract
Purpose: To characterize our experience and the disease control and toxicity of proton therapy (PT) for patients with head and neck cancer (HNC). Patients and Methods: Clinical outcomes for patients with HNC treated with PT at our institution were prospectively collected in 2 institutional review board–approved prospective studies. Descriptive statistics were used to summarize patient characteristics and outcomes. Overall survival, local-regional control, and disease-free survival were estimated by the Kaplan-Meier method. Treatment-related toxicities were recorded according to the Common Terminology Criteria for Adverse Events (version 4.03) scale. Results: The cohort consisted of 573 patients treated from February 2006 to June 2018. Media...
Add to ORKG